CCKAR and obesity due to melanocortin 4 receptor deficiency: Collectively, our work demonstrates that molecules with the key characteristics required for CCK1R PAM therapeutic development exist and thus opens the path for evolution of compounds for proof-of-concept evaluation of targeting augmentation of physiological CCK1R signaling for the treatment of obesity.